Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8429)
All Articles published online
|
Publishing Process of This Article
|
Sep 19, 2021 (publication date) through Sep 13, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Psychiatry
ISSN
2220-3206
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Maraone A, Tarsitani L, Pinucci I, Pasquini M. Antiglutamatergic agents for obsessive-compulsive disorder: Where are we now and what are possible future prospects? World J Psychiatr 2021; 11(9): 568-580 [PMID: 34631461 DOI: 10.5498/wjp.v11.i9.568] |
|---|---|
| URL: | https://www.wjgnet.com/2220-3206/full/v11/i9/568.htm |
| Number | Citing Articles |
| 1 |
Rakesh Sahu. Exploring Biomarkers and Contributing Factors in Obsessive-Compulsive Disorder: Hypothesis. Academic Bulletin of Mental Health 2024; 2: 54 doi: 10.25259/ABMH_12_2024
|
| 2 |
Hasan Mirzazadeh, Younes Ghaeminia, Amin Mohamad Niaei, Mohammadsadegh Kamran, Leila Razeghian Jahromi, Reza Moshfeghinia. Memantine augmentation of escitalopram in treatment of executive function among patients with obsessive-compulsive disorder (OCD): a double-blind placebo-controlled randomized clinical trial. BMC Psychiatry 2025; 25(1) doi: 10.1186/s12888-025-06856-7
|
| 3 |
Annalisa Maraone, Alessandro Trebbastoni, Antonella Di Vita, Fabrizia D'Antonio, Carlo De Lena, Massimo Pasquini. Memantine for Refractory Obsessive-Compulsive Disorder: Protocol for a Pragmatic, Double-blind, Randomized, Parallel-Group, Placebo-Controlled, Monocenter Trial. JMIR Research Protocols 2023; 12: e39223 doi: 10.2196/39223
|
| 4 |
Júlia Grigorini Mori Ayub, Cristina Luz Tosta, Breno Lopes Macedo, Tattyanna Fernandes Barreto, Lorena Martins Lopes, Maria Paula dos Santos Fracalossi, Roberto Andreatini, Vanessa Beijamini. S-ketamine exerts sex- and dose-dependent anti-compulsive-like effect as monotherapy or in augmentation to fluoxetine. European Journal of Pharmacology 2022; 937: 175382 doi: 10.1016/j.ejphar.2022.175382
|
| 5 |
Behnaz Bakhshinejad, Abdolreza Sabahi, Tania Dehesh, Zarrin Sarhadynejad, Mehrnaz Mehrabani, Mahdiyeh Khazaneha, Mehrzad Mehrbani, Mitra Mehrabani. Efficacy of the herbal product of Cuscuta campestris Yunck. and Polypodium vulgare L. in patients with obsessive-compulsive disorder: A triple-blind clinical trial. Journal of Ethnopharmacology 2026; 354: 120452 doi: 10.1016/j.jep.2025.120452
|
| 6 |
Sydney Raboin. Visualizing victory: the role of imagery in empowering athletes battling obsessive-compulsive disorder. Journal of Imagery Research in Sport and Physical Activity 2024; 19(s1) doi: 10.1515/jirspa-2024-0006
|
| 7 |
Rituparna Maiti, Archana Mishra, Anand Srinivasan, Biswa Ranjan Mishra. Pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive–compulsive disorder: A network meta‐analysis. Acta Psychiatrica Scandinavica 2023; 148(1): 19 doi: 10.1111/acps.13568
|